Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Date:10/26/2009

cur after the date hereof. This press release and prior releases are available at www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
        Lauren Fischer
        Director, Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5962
        E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... "North America Orthopedic Braces and Supports Market Outlook to ... Orthopedic Braces and Supports market. The report provides value, ... and average price data (in US dollars), within market ... , Ankle Braces and Supports , Spinal Braces ... Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... Society of Association Executives (ASAE) announced its 2014 Power ... the American Society of Anesthesiologists (ASA). , The ... of A Gold Award, one of the top honors ... betterment of the world through education on the global ... anesthesia care. , ASA was also honored with a ...
(Date:7/24/2014)... Pools and beaches are the place to be on ... for small children, so Amica Insurance is sharing ... Centers for Disease Control and Prevention, children between the ages ... injuries and deaths. It’s important to know the best practices ... offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... News Facts , Lexmark’s Perceptive ... for compliance with Department of Defense (DoD) security ... Information Assurance Certification and Accreditation Process (DIACAP). The ... DoD as the Enterprise Clinical Imaging Archive, has ... U.S. Army Medical Materiel Agency. , DIACAP certification ...
(Date:7/24/2014)... A new study led by the Translational Genomics Research ... viruses and the immune system during HIV infection. , ... to infect others based on their blood viral ... in their semen despite having low levels in their ... the virus can be found in different parts of ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2
... 10 Enstar Group,Limited ("Enstar") (Nasdaq: ... Enstar Australia Holdings Pty Limited, had entered ... AMP Limited ("AMP") of AMP,s,Australian-based closed reinsurance ... of AUS$585 million (approximately US$518 million)., ...
... it may cause the effect through cerebrovascular disease , ... may be associated with increased risk for mild cognitive ... University Medical Center in New York City. , Mild ... "attracted increasing interest during the past years, particularly as ...
... People rate their smiles higher than dentists do, according ... most important features of an attractive face, the study also ... with their smiles., The study, published in this months Journal ... Norway to rate their own smiles on a 100-point satisfaction ...
... Scheduled for 4:00 p.m. Eastern Time to Review Clinical, Trial ... ... the ASH Meeting, ATLANTA, Dec. 10 ... developing,novel anticancer therapeutics, presented positive results for SNS-595 in,relapsed or refractory ...
... of MGCD0103 Determined as 90 mg, * 53% of Patients ... Responses Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ... (TSX: MYG) today announced maturing data,from the Phase 1/2 study investigating the ...
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
Cached Medicine News:Health News:Enstar Group Limited Announces Acquisition 2Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 3Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 4Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 5Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:2007 Human Research Protection Award Recipients Announced 2
The AutoSet Respond offers ResMeds unique AutoSet algorithm and product quality in a convenient, affordable model. The AutoSet algorithm responds to the patients pressure needs on a breath-by-breath ...
... The AutoSet Spirit is the premium ... flow generators, S7. The AutoSet algorithm responds ... breath-by-breath basis. The flow generator stores and ... software. The AutoSet devices combine integrated ...
These products are primarily for use with paediatric patients and for patients with difficult veins....
... Blood Collection Sets allow you to ... safety. The BD Vacutainer® Safety-Lok™ Blood ... be shielded with one-handed activation. This ... and infusion procedures. It comes with ...
Medicine Products: